European Commission on June 4 authorised Pfizer-BioNTech’s Covid-19 vaccine for use in children as young as 12, paving the way for a broader roll-out in the bloc after similar clearances in the United States & Canada. However, vaccinating adolescents in affluent countries while many parts of the world await doses for older & more vulnerable people has raised concerns, with the World Health Organization urging rich countries to give shots to the COVAX scheme instead. Meanwhile, the All India Institute of Medical Sciences (AIIMS) is expected to start screening of children for clinical trials of India-made Covid-19 vaccine Covaxin from June 7. Last week, AIIMS Patna started a similar trial for Bharat Biotech's children aged between 12 & 18. After getting permission from the Drugs Controller General of India (DCGI), AIIMS Delhi is now starting the screening process before starting the actual trials, news agency ANI reported. India has three Covid-19 vaccine - Bharat Biotech's Covaxin, AstraZeneca's Covishield & Russia's Sputnik V.
Google Trends